DroneShield Limited (ASX:DRO)

Theseus Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	57.53	54.09	16.89	10.6	5.56
Other Revenue	0.48	0.12	-	-	-
Revenue	58.01	54.2	16.89	10.6	5.56
Revenue Growth (YoY)	7.02%	221.00%	59.33%	90.69%	57.86%
Cost of Revenue	16.28	15.14	4.98	2.85	1.83
Gross Profit	41.73	39.07	11.91	7.75	3.73
Selling, General & Admin	28.29	20.02	7.78	7.76	5
Research & Development	21.82	11.06	6.62	5.57	3.29
Other Operating Expenses	-	-	-0.11	-0.27	-0.82
Operating Expenses	54.75	36.35	15	14.22	9.98
Operating Income	-13.02	2.71	-3.09	-6.47	-6.25
Interest Expense	-0.46	-0.03	-	-	-
Interest & Investment Income	5.91	0.97	-	-	-
Currency Exchange Gain (Loss)	0.78	-0.49	0.16	0.08	-0.5
Pretax Income	-6.79	3.17	-2.93	-6.4	-6.75
Income Tax Expense	-5.47	-6.17	-1.98	-1.09	-0.88
Net Income	-1.32	9.34	-0.95	-5.31	-5.87
Net Income to Common	-1.32	9.34	-0.95	-5.31	-5.87
Shares Outstanding (Basic)	625	464	430	398	299
Shares Outstanding (Diluted)	674	475	430	398	299
Shares Change (YoY)	41.79%	10.59%	8.06%	33.04%	39.75%
EPS (Basic)	-0.00	0.02	-0.00	-0.01	-0.02
EPS (Diluted)	-0.00	0.02	-0.00	-0.01	-0.02
Free Cash Flow	-68.56	7.75	-2.6	-6.78	-5.43
Free Cash Flow Per Share	-0.10	0.02	-0.01	-0.02	-0.02
Gross Margin	71.93%	72.07%	70.53%	73.12%	67.13%
Operating Margin	-22.44%	5.00%	-18.30%	-61.09%	-112.51%
Profit Margin	-2.27%	17.22%	-5.62%	-50.11%	-105.56%
Free Cash Flow Margin	-118.18%	14.30%	-15.39%	-63.95%	-97.73%
EBITDA	-10.71	3.69	-2.75	-6.09	-5.78
EBITDA Margin	-18.46%	6.81%	-16.26%	-57.43%	-103.93%
D&A For EBITDA	2.31	0.98	0.34	0.39	0.48
EBIT	-13.02	2.71	-3.09	-6.47	-6.25
EBIT Margin	-22.44%	5.00%	-18.30%	-61.09%	-112.51%

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.